Cargando…

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma

PURPOSE: We explored the effect of hepatocyte growth factor (HGF)/Met signaling pathway on nasopharyngeal carcinoma (NPC) cells in vitro and in vivo, and investigated the ability of Met tyrosine kinase inhibitor (TKI) to block HGF-induced biological signaling. EXPERIMENTAL DESIGN: Met TKI inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yuanyuan, Zhang, Jing, Tian, Ying, Xue, Cong, Hu, Zhihuang, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555972/ https://www.ncbi.nlm.nih.gov/pubmed/26345996 http://dx.doi.org/10.2147/DDDT.S85837

Ejemplares similares

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
por: Hong, Shaodong, et al.
Publicado: (2014)

Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor
por: Cho, Oyeon, et al.
Publicado: (2015)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
por: Mekki, Meriem Sarah, et al.
Publicado: (2018)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis
por: Han, Yingjie, et al.
Publicado: (2018)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
por: Glen, Hilary, et al.
Publicado: (2011)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
por: Zhang, Yazhuo, et al.
Publicado: (2018)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2017)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET
por: Li, Y-Q, et al.
Publicado: (2015)

Human Aurora kinase inhibitor Hesperadin reveals epistatic interaction between Plasmodium falciparum PfArk1 and PfNek1 kinases
por: Morahan, Belinda J., et al.
Publicado: (2020)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase
por: Fernandes, Marie, et al.
Publicado: (2019)

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
por: Koo, Karen, et al.
Publicado: (2023)

SAM domain-dependent activity of PfTKL3, an essential tyrosine kinase-like kinase of the human malaria parasite Plasmodiumfalciparum
por: Abdi, Abdirahman, et al.
Publicado: (2010)

Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
por: Li, Wenjing, et al.
Publicado: (2019)

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
por: Hsu, Jeff, et al.
Publicado: (2023)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Regulation of growth, invasion and metabolism of breast ductal carcinoma through CCL2/CCR2 signaling interactions with MET receptor tyrosine kinases
por: Acevedo, Diana Sofía, et al.
Publicado: (2022)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
por: Qu, Kai, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r120o6e4apecu0nmqlstgapmr2